COVID-19 has exacerbated fractures in our healthcare and social delivery systems, including adverse social risk factors. Precision's Maureen Hennessey discusses strategies pharmaceutical manufacturers must adopt to address social determinants of health and population health management challenges during the COVID-19 pandemic and beyond.
Congratulations to Precision's Jeremy Schafer, who has been named one of the 2020 PM360 ELITE 100 in the Strategist category!
Precision's Jeremy Schafer and Deborah Lotterman discuss how to use vaccine messaging based on our shared coronavirus experiences to improve vaccination rates and educate the public on their importance.
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
